NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Mannatech Inc. MTEX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$108.0M
▼ 8.3% vs FY2024
EPS · FY25
$-8.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-897.3%
Net margin · FY25
-14.1%
Dividend coverage
-6.0×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 108.0M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 14 cents on every revenue dollar this year.
Per share
USD -8.00
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-897.3%
Return on equity, FY2025
ROE
Operating margin-0.4%
Net margin-14.1%
Return on assets-46.1%
Each USD of equity lost 897 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−6.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−7.7%
−6.5%
−5.0%
−4.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years−8.2%
Change, 10 years−29.1%
The share count shrank 8% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 30.0M
total assets, end of FY2025
Total assetsUSD 30.0M
EquityUSD -5.2M
CashUSD 6.2M
Gross debtUSD 2.8M
Net debtUSD -3.4M
Current ratio1.10×
The company holds more cash than debt.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.1
0.1
0.1
0.1
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.3
0.3
0.4
Operating income $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
Net income $B
−0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−8.00
1.32
−1.20
−2.35
4.71
2.77
1.35
−1.53
−0.66
−0.22
2.14
2.40
1.18
−0.52
−7.80
−4.01
−6.56
−0.48
0.25
Dividend / sh $
·
·
0.20
·
·
·
·
·
·
·
·
·
·
·
·
0.00
0.04
0.22
0.36
Payout %
·
0
−33
−34
44
54
36
−79
−76
−115
0
·
·
·
−0
−0
−6
−46
144
ROE %
−897.3
26.1
−18.2
−23.3
39.1
23.5
12.5
−11.9
−4.5
−1.5
16.7
23.7
14.5
−6.6
−65.9
−25.8
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed